Shizuka Kaneko
Wakayama, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications
[18F]FB(ePEG12)12-Exendin-4 positron emission tomography/magnetic resonance imaging for precise preoperative localization of a pancreatic-head insulinoma: a case report with review of literature.
Journal: Endocrine journal
Published: March 15, 2026
Delayed Onset Immune-Related Pituitary Adrenal Insufficiency Induced by Neoadjuvant Nivolumab Therapy for Locally Advanced Lung Cancer in the Postoperative Period: A Case Report.
Journal: Surgical case reports
Published: October 23, 2024
Development of Fulminant Type 1 Diabetes Mellitus in the Course of Treatment with Atezolizumab for Hepatocellular Carcinoma.
Journal: Internal medicine (Tokyo, Japan)
Published: October 26, 2022
Tirzepatide: A Novel, Once-weekly Dual GIP and GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes.
Journal: TouchREVIEWS in endocrinology
Published: January 31, 2022
Novel approaches to pharmacological management of type 2 diabetes in Japan.
Journal: Expert opinion on pharmacotherapy
Published: August 31, 2021
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.
Journal: Lancet (London, England)
Published: May 21, 2021
Benefit of Early Add-on of Linagliptin to Insulin in Japanese Patients With Type 2 Diabetes Mellitus: Randomized-Controlled Open-Label Trial (TRUST2).
Journal: Advances in therapy
Published: December 17, 2020
A Japanese Study Assessing Glycemic Control with Use of IDegAsp Co-formulation in Patients with Type 2 Diabetes in Clinical Practice: The JAGUAR Study.
Journal: Advances in therapy
Published: November 12, 2020
Efficacy and safety of the fixed-ratio combination of insulin degludec and liraglutide by baseline glycated hemoglobin, body mass index and age in Japanese individuals with type 2 diabetes: A subgroup analysis of two phase III trials.
Journal: Journal of diabetes investigation
Published: October 26, 2020
Superior HbA1c control with the fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with a maximum dose of 50 units of insulin degludec in Japanese individuals with type 2 diabetes in a phase 3, double-blind, randomized trial.
Journal: Diabetes, obesity & metabolism
Published: March 29, 2019
GLP1 Receptor Agonist Liraglutide Is an Effective Therapeutic Option for Perioperative Glycemic Control in Type 2 Diabetes within Enhanced Recovery After Surgery (ERAS) Protocols.
Journal: European surgical research. Europaische chirurgische Forschung. Recherches chirurgicales europeennes
Published: April 14, 2018
Efficacy and safety of subgroup analysis stratified by baseline HbA1c in a Japanese phase 3 study of dulaglutide 0.75 mg compared with insulin glargine in patients with type 2 diabetes.
Journal: Endocrine journal
Published: September 15, 2017
Last Updated: 09/26/2026